Jialiang Zhang

Jialiang Zhang

Auto-generated profile, based on publicly available information

Jialiang Zhang

Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China and Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2019 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
LTLiping Tan
Liping Tan
DMDongmei Mai
Dongmei Mai
ZBZHANG Bailin
ZHANG Bailin
XJXiao-Bing Jiang
Xiao-Bing Jiang
JZJialiang Zhang
Jialiang Zhang
DLDongxin Lin
Dongxin Lin
Breast cancer is one of the most common malignancies and the major cause of cancer-related death in women. Although the importance of PIWI-interacting RNAs (piRNAs) in cancer has been increasingly recognized, few studies have been explored the functional mechanism of piRNAs in breast cancer development and progression. We examined the top 20 highly expressed piRNAs based on the analysis of TCGA breast cancer data in two patient cohorts to test the roles of piRNAs in breast cancer. The effects of piRNA-36,712 on the malignant phenotypes and chemosensitivity of breast cancer cells were detected in vitro and in vivo. MS2-RIP and reporter gene assays were conducted to identify the interaction and regulation among piRNA-36,712, miRNAs and SEPW1P. Kaplan-Meier estimate with log-rank test was used to compare patient survival by different piRNA-36,712 expression levels. We found piRNA-36,712 level was significantly lower in breast cancer than in normal breast tissues and low level was correlated with poor clinical outcome in patients. Functional studies demonstrated that piRNA-36,712 interacts with RNAs produced by SEPW1P, a retroprocessed pseudogene of SEPW1, and subsequently inhibits SEPW1 expression through competition of SEPW1 mRNA with SEPW1P RNA for microRNA-7 and microRNA-324. We also found that higher SEPW1 expression due to downregulation of piRNA-36,712 in breast cancer may suppress P53, leading to the upregulated Slug but decreased P21 and E-cadherin levels, thus promoting cancer cell proliferation, invasion and migration. Furthermore, we found that piRNA-36,712 had synergistic anticancer effects with the paclitaxel and doxorubicin, two chemotherapeutic agents for breast cancer. These findings suggest that piRNA-36,712 is a novel tumor suppressor and may serve as a potential predictor for the prognosis of breast cancer patients.

13 November 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RLRui Li
Rui Li
HZHongzhe Zhao
Hongzhe Zhao
XHXudong Huang
Xudong Huang
JZJialiang Zhang
Jialiang Zhang
RBRuihong Bai
Ruihong Bai
JZJian Zheng
Jian Zheng

15 November 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
LPLing Pan
Ling Pan
XHXudong Huang
Xudong Huang
ZLZe-Xian Liu
Ze-Xian Liu
YYYing Ye
Ying Ye
RLRui Li
Rui Li
JZJian Zheng
Jian Zheng
The tumorigenic mechanism for pancreatic ductal adenocarcinoma (PDAC) is not clear, although chronic inflammation is implicated. Here, we identified an inflammatory cytokine–regulated transfer RNA–derived (tRNA-derived) fragment, tRF-21-VBY9PYKHD (tRF-21), as a tumor suppressor in PDAC progression. We found that the biogenesis of tRF-21 could be inhibited by leukemia inhibitory factor and IL-6 via the splicing factor SRSF5. Reduced tRF-21 promoted AKT2/1-mediated heterogeneous nuclear ribonucleoprotein L (hnRNP L) phosphorylation, enhancing hnRNP L to interact with dead-box helicase 17 (DDX17) to form an alternative splicing complex. The provoked hnRNP L-DDX17 activity preferentially spliced Caspase 9 and mH2A1 pre-mRNAs to form Caspase 9b and mH2A1.2, promoting PDAC cell malignant phenotypes. The tRF-21 levels were significantly lower in PDACs than in normal tissues, and patients with low tRF-21 levels had a poor prognosis. Treatment of mouse PDAC xenografts or patient-derived xenografts (PDXs) with tRF-21 mimics repressed tumor growth and metastasis. These results demonstrate that tRF-21 has a tumor-suppressive effect and is a potential therapeutic agent for PDAC.

26 May 2025 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ZCZiming Chen
Ziming Chen
YZYifan Zhou
Yifan Zhou
CXChunling Xue
Chunling Xue
LZLingxing Zeng
Lingxing Zeng
SDShuang Deng
Shuang Deng
JZJian Zheng
Jian Zheng

10 October 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YZYanfen Zheng
Yanfen Zheng
XLXingyang Li
Xingyang Li
SDShuang Deng
Shuang Deng
HZHongzhe Zhao
Hongzhe Zhao
YYYing Ye
Ying Ye
ZZZhixiang Zuo
Zhixiang Zuo
N6-methyladenosine (m6A) modification of gene transcripts plays critical roles in cancer. Here we report transcriptomic m6A profiling in 98 tissue samples from 65 individuals with pancreatic ductal adenocarcinoma (PDAC). We identify 17,996 m6A peaks with 195 hyper-methylated and 93 hypo-methylated in PDAC compared with adjacent normal tissues. The differential m6A modifications distinguish two PDAC subtypes with different prognosis outcomes. The formation of the two subtypes is driven by a newly identified m6A regulator CSTF2 that co-transcriptionally regulates m6A installation through slowing the RNA Pol II elongation rate during gene transcription. We find that most of the CSTF2-regulated m6As have positive effects on the RNA level of host genes, and CSTF2-regulated m6As are mainly recognized by IGF2BP2, an m6A reader that stabilizes mRNAs. These results provide a promising PDAC subtyping strategy and potential therapeutic targets for precision medicine of PDAC.

19 September 2023 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
GWGuandi Wu
Guandi Wu
JSJiachun Su
Jiachun Su
LZLingxing Zeng
Lingxing Zeng
SDShuang Deng
Shuang Deng
XHXudong Huang
Xudong Huang
JZJian Zheng
Jian Zheng